%0 Journal Article %A Amy X. Du %A Zarqa Ali %A Kawa K. Ajgeiy %A Maiken G. Dalager %A Tomas N. Dam %A Alexander Egebjerg %A Christoffer V. S. Nissen %A Lone Skov %A Simon Francis Thomsen %A Sepideh Emam %A Robert Gniadecki %T Machine Learning Model for Predicting Outcomes of Biologic Therapy in Psoriasis %D 2021 %R 10.1101/2021.12.05.21267219 %J medRxiv %P 2021.12.05.21267219 %X Background Biological agents used for the therapy of psoriasis lose efficacy over time, which leads to discontinuation of the drug. Optimization of long-term biologic treatment is an area of medical need but there are currently no prediction tools for biologic drug discontinuation.Objective To compare the accuracy of the risk factor-based frequentist statistical model to machine learning to predict the 5-year probability of biologic drug discontinuation.Methods The national Danish psoriasis biologic therapy registry, Dermbio, comprising 6,172 treatment series with anti-TNF (Etanercept, Infliximab, Adalimumab), Ustekinumab, Guselkumab and anti-IL17 (Secukinumab and Ixekizumab) in 3,388 unique patients was used as data source. Hazard ratios (HR) were computed for all available predictive factors using Cox regression analysis. Different machine learning (ML) models for the prediction of 5-year risk of drug discontinuation were trained using the 5-fold cross validation technique and using 10 clinical features routinely assessed in psoriasis patients as input variables. Model performance was assessed using the area under the receiver operating characteristic curve (AUC).Results The lowest 5-year risk of discontinuation was associated with therapy with ustekinumab or ixekizumab, male sex and no previous exposure to biologic therapy. The predictive model based on those risk factors had an AUC of 0.61. The best ML model (gradient boosted tree) had an AUC of 0.85.Conclusions A machine learning-based approach, more than a statistical model, accurately predicts the risk of discontinuation of biologic therapy based on simple patient variables available in clinical practice. ML might be incorporated into clinical decision making.Competing Interest StatementAXD, ZA, KKA, TND, AE, CVSE, and SE report no conflicts. MGD has served on advisory boards with AbbVie, Leo Pharma and Eli Lilly, and has received honoraria as a consultant from Eli Lilly. LS has received research funding from Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the LEO Foundation and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker for AbbVie, Eli Lilly, Novartis, Pfizer, and LEO Pharma, Janssen, UCB, Almirall, Bristol-Myers Squibb, Boehringer Ingelheim and Sanofi. She has served as an investigator for AbbVie, Pfizer, Sanofi, Janssen, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, Galderma and LEO Pharma. SFT has been a paid speaker for AbbVie, Eli Lilly, Novartis, Sanofi, Pierre Fabre, GSK and LEO Pharma, and has served on Advisory Boards with AbbVie, Eli Lilly, Janssen, Novartis, Roche, Sanofi, UCB, and LEO Pharma. He has served as an investigator for AbbVie, AstraZeneca, Boehringer, UCB, CSL and Novartis and received research grants from AbbVie, Novartis, Sanofi and UCB. RG reports carrying out clinical trials for AbbVie and Janssen and has received honoraria as a consultant and/or speaker from AbbVie, Bausch Health, Eli Lilly, Janssen, Mallincrodt, Novartis, and Sanofi. The authors do not have equity in pharmaceutical companies.Funding StatementThis study was funded by a start-up grant from the Department of Medicine, University of Alberta to RG. AXD was supported by summer studentships from Alberta Innovates and the Canadian Association of Psoriasis Patients.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee/IRB of the University of Alberta gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. %U https://www.medrxiv.org/content/medrxiv/early/2021/12/07/2021.12.05.21267219.full.pdf